NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»01/04/2010 [Industry news]
Teijin, Astellas join hands for Chinese market

Japanese pharma companies, Teijin Pharma and the two subsidiaries of Astellas, namely Astellas Pharma China and Astellas Pharma Hong Kong, have entered into an agreement regarding the marketing of TMX-67 (febuxostat) in China and Hong Kong respectively.

 
Japanese pharma companies, Teijin Pharma and the two subsidiaries of Astellas, namely Astellas Pharma China and Astellas Pharma Hong Kong, have entered into an agreement regarding the marketing of TMX-67 (febuxostat) in China and Hong Kong respectively. TMX-67 is a novel drug discovered by Teijin Pharma for the treatment of hyperuricemia in patients with gout. In China, Teijin Pharma and Astellas China will co-develop and manage approval process of TMX-67. Sales in the Chinese market will be handled by Astellas China after its commercial launch, which is targeted at 2014. Teijin Pharma also holds co-promotion rights in Shanghai. In Hong Kong, Astellas Hong Kong will manage the approval process and handle sales after its commercial launch targeted at 2011. Teijin Pharma will supply the finished product and receive an upfront licensing fee as well as commercial milestone payments. TMX-67, developed by Teijin Pharma, is an oral, once-daily, highly potent, non-purine selective inhibitor of xanthine oxidase. According to the company, the current leading medication, allopurinol, was developed nearly 40 years ago, so a new drug that provides more options for the treatment of gout and hyperuricemia has long been sought. TMX-67 has proven therapeutic superiority to allopurinol and above all is well tolerated by patients suffering from a mild and moderate renal impairment. Teijin Pharma hopes to contribute to the quality of life in gout patients in China and Hong Kong, as well as other areas around the globe, by continuing to pursue collaborative efforts to broaden TMX-67’s global availability. Astellas has already established its business platform in Asia. Particularly the sales of Astellas China is currently growing over 10 percent. Astellas expects to further expand the business in China and Hong Kong by entering TMX-67 into the market.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.